Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline

(2012) Ulf Kallweit et al.   CLINICAL NEUROPHARMACOLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

(2011) J Theodore Phillips et al.   Multiple Sclerosis Journal

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

(2010) Norman Putzki et al.   EUROPEAN NEUROLOGY

Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

(2010) F. Sangalli et al.   NEUROLOGICAL SCIENCES

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY